1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on April 19, 2025

REGN

MT Newswires

2 days ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $865 From $903

FDA to review Regeneron’s sBLA for aflibercept injection 8mg
REGN

Pharmaceutical Technology

2 days ago

FDA to review Regeneron’s sBLA for aflibercept injection 8mg

REGN

MT Newswires

2 days ago

Regeneron Says Application for Expanded Use of Eylea Accepted for FDA Priority Review

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
REGN

GlobeNewswire

2 days ago

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
REGN

StockStory

4 days ago

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
REGN

StockStory

5 days ago

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

REGN

MT Newswires

8 days ago

Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $600 From $750, Keeps Neutral Rating

REGN

MT Newswires

8 days ago

Goldman Sachs Cuts Price Target on Regeneron Pharmaceuticals to $917 From $1,019, Keeps Buy Rating

REGN

Morningstar Research

9 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN

MT Newswires

9 days ago

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $940 From $950, Maintains Buy Rating

REGN

MT Newswires

10 days ago

Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $1,081 From $1,150, Keeps Overweight Rating

REGN

MT Newswires

12 days ago

Jefferies Adjusts Regeneron Pharmaceuticals' Price Target to $936 rom $1,120, Keeps Buy Rating

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
REGN

Motley Fool

12 days ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
REGN

StockStory

12 days ago

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan
REGN

Simply Wall St.

14 days ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
REGN

Motley Fool

14 days ago

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years

REGN

MT Newswires

16 days ago

Oppenheimer Adjusts PT on Regeneron Pharmaceuticals to $925 From $950, Maintains Outperform Rating

REGN

MT Newswires

16 days ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $1,051 From $1,045, Keeps Outperform Rating

REGN

MT Newswires

16 days ago

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $979 From $1,010, Maintains Outperform Rating

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?
REGN

Insider Monkey

17 days ago

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?

Biotech stocks slide as Marks resignation seen being negative for sector
REGN

TipRanks

18 days ago

Biotech stocks slide as Marks resignation seen being negative for sector

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
REGN

Zacks

18 days ago

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

REGN

MT Newswires

18 days ago

Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $780 From $834, Keeps Outperform Rating

Intellia Focuses on Pipeline Development Amid Stiff Competition
REGN

Zacks

19 days ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
REGN

Zacks

19 days ago

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

REGN

MT Newswires

19 days ago

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $1,000 From $1,100, Maintains Overweight Rating

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows
REGN

Insider Monkey

20 days ago

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows

REGN

MT Newswires

22 days ago

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
REGN

GlobeNewswire

22 days ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts
REGN

Insider Monkey

25 days ago

Is Regeneron Pharmaceuticals, Inc. (REGN) a Promising Biotech Stock According to Wall Street Analysts

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
REGN

GlobeNewswire

25 days ago

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
REGN

Zacks

25 days ago

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?
REGN

Insider Monkey

25 days ago

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Extremely Profitable Stocks to Buy According to Analyst?

3 Reasons to Sell REGN and 1 Stock to Buy Instead
REGN

StockStory

a month ago

3 Reasons to Sell REGN and 1 Stock to Buy Instead

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
REGN

StockStory

a month ago

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires

Jim Cramer Wants You to ‘Own’ Regeneron Pharmaceuticals (REGN) Shares
REGN

Insider Monkey

a month ago

Jim Cramer Wants You to ‘Own’ Regeneron Pharmaceuticals (REGN) Shares

Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results
REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off
REGN

StockStory

a month ago

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

REGN

MT Newswires

a month ago

Argus Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $1,000

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

REGN

MT Newswires

a month ago

Regeneron Shares Fall After US Appeals Court Denies Request for Stay on Eylea Biosimilars

REGN

Argus Research

a month ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

a month ago

Market Update: MDU, REGN, DG, BHF

Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) – “I Want You to Own It”
REGN

Insider Monkey

a month ago

Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) – “I Want You to Own It”

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds?
REGN

Insider Monkey

a month ago

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Pharma Stock to Buy According to Hedge Funds?

Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?
REGN

Zacks

a month ago

Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report?

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
REGN

PR Newswire

a month ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
REGN

GlobeNewswire

a month ago

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now

S&P 500 Gains and Losses Today: Index Tumbles as Economic Concerns Intensify
REGN

Investopedia

a month ago

S&P 500 Gains and Losses Today: Index Tumbles as Economic Concerns Intensify

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
REGN

Motley Fool

a month ago

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
REGN

GlobeNewswire

a month ago

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
REGN

Zacks

a month ago

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
REGN

Zacks

a month ago

Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?

Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Performing Large Cap Stock to Buy According to Analysts?
REGN

Insider Monkey

2 months ago

Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Performing Large Cap Stock to Buy According to Analysts?

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
REGN

Zacks

2 months ago

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

REGN

MT Newswires

2 months ago

Regeneron Says Linvoseltamab Recommended for EU Approval to Treat Multiple Myeloma

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
REGN

GlobeNewswire

2 months ago

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Regeneron makes second bid for blood cancer therapy approval
REGN

Pharmaceutical Technology

2 months ago

Regeneron makes second bid for blood cancer therapy approval

REGN

MT Newswires

2 months ago

Regeneron Says US FDA Accepts for Review Resubmission of Application for Follicular Lymphoma Drug

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
REGN

GlobeNewswire

2 months ago

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts
REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts

Regeneron gene therapy helps deaf children hear in small study
REGN

BioPharma Dive

2 months ago

Regeneron gene therapy helps deaf children hear in small study

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
REGN

GlobeNewswire

2 months ago

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts
REGN

Insider Monkey

2 months ago

Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
REGN

Zacks

2 months ago

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

2 Healthcare Stocks with Big Upside and 1 to Skip
REGN

StockStory

2 months ago

2 Healthcare Stocks with Big Upside and 1 to Skip

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
REGN

Investopedia

2 months ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

This Company Just Initiated a Quarterly Dividend: Time to Buy?
REGN

Motley Fool

2 months ago

This Company Just Initiated a Quarterly Dividend: Time to Buy?

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
REGN

Zacks

2 months ago

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
REGN

Pharmaceutical Technology

2 months ago

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
REGN

GlobeNewswire

2 months ago

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
REGN

Zacks

2 months ago

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders
REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders

Regeneron Announces Investor Conference Presentations
REGN

GlobeNewswire

2 months ago

Regeneron Announces Investor Conference Presentations

REGN

MT Newswires

2 months ago

Regeneron Pharmaceuticals' Blood Cancer Drug Application Accepted by FDA

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
REGN

GlobeNewswire

2 months ago

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

REGN

MT Newswires

2 months ago

Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,200, Maintains Buy Rating

Regeneron’s macular oedema therapy shows promise in Phase III trial
REGN

Clinical Trials Arena

2 months ago

Regeneron’s macular oedema therapy shows promise in Phase III trial

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
REGN

Motley Fool

2 months ago

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
REGN

Simply Wall St.

2 months ago

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
REGN

StockStory

2 months ago

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
REGN

GlobeNewswire

2 months ago

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
REGN

GlobeNewswire

2 months ago

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

REGN

Morningstar Research

2 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
REGN

Zacks

2 months ago

Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval

REGN

MT Newswires

2 months ago

Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $1,010 From $1,000

REGN

MT Newswires

2 months ago

Baird Adjusts Regeneron Pharmaceuticals Price Target to $759 From $940

REGN

MT Newswires

2 months ago

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,019 From $1,182

REGN

MT Newswires

2 months ago

Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $1,150 From $1,185

REGN

MT Newswires

2 months ago

UBS Adjusts Price Target on Regeneron Pharmaceuticals to $768 From $738, Maintains Neutral Rating

REGN

MT Newswires

2 months ago

RBC Trims Price Target on Regeneron Pharmaceuticals to $1,045 From $1,059, Keeps Outperform Rating

REGN

MT Newswires

2 months ago

Leerink Upgrades Regeneron Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $834 From $762

Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
REGN

Simply Wall St.

2 months ago

Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Company News for Feb 5, 2025
REGN

Zacks

2 months ago

Company News for Feb 5, 2025

Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
REGN

GuruFocus.com

2 months ago

Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...

REGN

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
REGN

Motley Fool

2 months ago

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

Share on Social Networks: